synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
small ubiquitin-like modifier (SUMO) Any of a family of small proteins, each approximately 100 amino acids, which are covalently conjugated to and removed from charged residues of other proteins in a form of post-translational modification known as SUMOylation, thereby functioning as a protein tag in a manner resembling ubiquitin.
at IBM of methods to specifically produce single-walled carbon nanotubes by adding transition-metal catalysts to the carbon in an arc discharge. Thess et al. refined this catalytic method by vaporizing the carbon/transition-metal combination in a high-temperature furnace, which greatly improved the yield and purity of the SWNTs and made them widely available for characterization and application experiments. The arc discharge technique, well known to produce the famed Buckminsterfullerene, thus played a role in the discoveries of both multi- and single-wall nanotubes, extending the run of serendipitous discoveries relating to fullerenes. The discovery of nanotubes remains a contentious issue. Many believe that Iijima's report in 1991 is of particular importance because it brought carbon nanotubes into the awareness of the scientific community as a whole. In 2020, during an archaeological excavation of Keezhadi in Tamil Nadu, India, ~2600-year-old pottery was discovered whose coatings appear to contain carbon nanotubes. The robust mechanical properties of the nanotubes are partially why the coatings have lasted for so many years, say the scientists.
== Steric complementarity == In her third paper on cyclols (1936), Wrinch noted that many "physiologically active" substances such as steroids are composed of fused hexagonal rings of carbon atoms and, thus, might be sterically complementary to the face of cyclol molecules without the amino-acid side chains. Wrinch proposed that steric complementarity was one of chief factors in determining whether a small molecule would bind to a protein. Wrinch speculated that proteins are responsible for the synthesis of all biological molecules. Noting that cells digest their proteins only under extreme starvation conditions, Wrinch further speculated that life could not exist without proteins.
By 1936, the pool of missing elements from hydrogen to uranium had shrunk to four: elements 43, 61, 85, and 87 remained missing. Element 43 eventually became the first element to be synthesized artificially via nuclear reactions rather than discovered in nature. It was discovered in 1937 by Italian chemists Emilio Segrè and Carlo Perrier, who named their discovery technetium, after the Greek word for "artificial". Elements 61 (promethium) and 85 (astatine) were likewise produced artificially in 1945 and 1940 respectively; element 87 (francium) became the last element to be discovered in nature, by French chemist Marguerite Perey in 1939. The elements beyond uranium were likewise discovered artificially, starting with Edwin McMillan and Philip Abelson's 1940 discovery of neptunium (via bombardment of uranium with neutrons). Glenn T. Seaborg and his team at the Lawrence Berkeley National Laboratory (LBNL) continued discovering transuranium elements, starting with plutonium in 1941, and discovered that contrary to previous thinking, the elements from actinium onwards were congeners of the lanthanides rather than transition metals. Bassett (1892), Werner (1905), and the French engineer Charles Janet (1928) had previously suggested this, but their ideas did not then receive general acceptance. Seaborg thus called them the actinides. Elements up to 101 (named mendelevium in honour of Mendeleev) were synthesized up to 1955, either through neutron or alpha-particle irradiation, or in nuclear explosions in the cases of 99 (einsteinium) and 100 (fermium).
Sources: en.wikipedia.org
== Usage == Drug use among elderly Americans has been studied; in a group of 2,377 people with an average age of 71 surveyed between 2005 and 2006, 84% took at least one prescription drug, 44% took at least one over-the-counter (OTC) drug, and 52% took at least one dietary supplement; in a group of 2245 elderly Americans (average age of 71) surveyed over the period 2010 – 2011, those percentages were 88%, 38%, and 64%.
== Measurement techniques == The choice of various conventional or in-situ analysis techniques affects the resolution, precision, detection limits and cost of monazite geochronology. The recent analytical progress in U-Th-Pb system in natural monazite has been mainly achieved by (1) Isotope Dilution Thermal Ionization Mass Spectrometry (ID-TIMS), (2) Secondary Ion Mass Spectrometry (SIMS), (3) Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) and (4) Electronic Microprobe Analyses (EMPA).
In September 1947, the Soviets created Cominform to impose orthodoxy within the international communist movement and tighten political control over Soviet satellites through coordination of communist parties in the Eastern Bloc. Cominform faced an embarrassing setback the following June, when the Tito–Stalin split obliged its members to expel Yugoslavia, which remained communist but adopted a non-aligned position and began accepting financial aid from the US. Besides Berlin, the status of the city of Trieste was at issue. Until the break between Tito and Stalin, the Western powers and the Eastern bloc faced each other uncompromisingly. In addition to capitalism and communism, Italians and Slovenes, monarchists and republicans as well as war winners and losers often faced each other irreconcilably. The neutral buffer state Free Territory of Trieste, founded in 1947 with the United Nations, was split up and dissolved in 1954 and 1975, also because of the détente between the West and Tito.
=== Books === In 2003, Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic by the journalist Barry Meier was published. In 2023, Netflix adapted the book into the drama miniseries Painkiller. In 2015, Dreamland: The True Tale of America's Opiate Epidemic by Sam Quinones was released, which connected the growth of the U.S. opioid epidemic to the production and distribution of black-tar heroin from Mexico. In 2018, Dopesick: Dealers, Doctors, and the Drug Company that Addicted America by Beth Macy was released. The book covered the origin and evolution of the opioid epidemic in the United States beginning primarily with the 1996 release of the drug OxyContin, examining on its effects on small town America and the Appalachian region in particular. It received the Los Angeles Times Book Prize for Science and Technology. In 2021, Hulu adapted the book into a drama miniseries, also titled Dopesick, starring Michael Keaton. In 2021, Empire of Pain: The Secret History of the Sackler Dynasty by Patrick Radden Keefe was published, examining the history of the Sackler family, including the founding of Purdue Pharma, its role in the marketing of pharmaceuticals, and the family's central role in the opioid epidemic. The book followed Keefe's 2017 article on the Sackler family in The New Yorker, titled "The Family That Built an Empire of Pain". The book received multiple awards and was longlisted for the 2022 Andrew Carnegie Medal for Excellence in Nonfiction. In 2023, Netflix adapted Keefe's article and Meier's book into the drama miniseries Painkiller.
CIS is a first episode of MS signs and symptoms, followed by a full or almost full recovery. To be classified as CIS, the attack must last at least a full day and be due to demyelination or inflammation of the central nervous system. Individuals with CIS can in some cases be diagnosed directly with MS, if they meet more strict criteria compared to people with a history of attacks. Radiologically isolated syndrome is diagnosed when an MRI for an unrelated issue shows MS-like lesions. Similarly, people can be diagnosed with MS if they meet more strict criteria. RRMS is characterized by unpredictable relapses followed by periods of weeks to years of relative quiet (remission). Deficits that occur during attacks may either resolve fully or leave some problems. In between attacks, there is often silent progression of the disease (progression independent of relapse activity). RRMS describes the initial course of 85% of individuals with MS. RRMS can sometimes develop into SPMS, as attack frequency declines and there is clear worsening between attacks. In practical terms, the diagnosis of SPMS is typically only made in people with a minimum amount of disability. Occasional relapses and minor remissions may appear. Less frequently, MS starts as PPMS, which is characterised by a progressive worsening in the absence of attacks, from disease onset. Symptoms may become slightly less severe temporarily.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.